# A & G Pharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/a-g-pharmaceutical

- Industry: Pharmaceuticals
- Headquarters: Columbia, US
- Website: www.agpharma.com
- Total disclosed funding: $2M
- Latest round: Series A (Sep 8, 2005)
- Investors on record: 3

## About

A & G Pharmaceutical is dedicated to developing and distributing innovative pharmaceutical solutions, with a focus on improving health outcomes through effective medications and remedies for chronic diseases and common ailments.Founded in 2000 in Columbia, US, A & G Pharmaceutical is engaged in the development and distribution of pharmaceutical products. The company has closed 6 deals, the most recent being a grant financing round in May 2013, where it raised USD 0.30 mn from Avon Foundation. The firm is led by CEO Ginette Serrero, who co-founded the company along with Gordon Sato and Jun Hayashi.A&G Pharmaceutical specializes in the development and distribution of innovative pharmaceutical products aimed at addressing various health conditions. The company’s core product offerings include prescription medications that target chronic diseases, as well as over-the-counter remedies designed to alleviate common ailments. These products are developed through rigorous research and clinical trials, ensuring they meet safety and efficacy standards before reaching the market. A&G Pharmaceutical serves a diverse client base, including healthcare providers, pharmacies, and hospitals, primarily in North America and select countries in Europe and Asia. The end users of these products range from patients seeking treatment for their conditions to healthcare professionals prescribing these medications as part of a comprehensive treatment plan.A&G Pharmaceutical generates revenue through a structured business model that includes direct sales to healthcare providers and partnerships with pharmacies and hospitals. The company operates on a B2B model, supplying its flagship products to a network of wholesalers and distributors who facilitate broader access to end consumers. Revenue is driven by both one-time purchases and ongoing contracts for replenishing stock, with various pricing plans structured to incentivize bulk purchases by healthcare institutions. A&G Pharmaceutical's offerings include proprietary medications that have established a strong market presence, contributing significantly to its financial stability. The revenue structure is designed to support sustainable growth while ensuring that clients have continuous access to essential pharmaceutical products.A&G Pharmaceutical plans to utilize the USD 0.30 mn raised in grant financing from Avon Foundation in May 2013 to support the development of new products targeting chronic diseases and expand into international markets. The company aims to launch innovative treatments by the end of 2024, with a focus on increasing its presence in select countries in Europe and Asia.

## Funding rounds

- Series A, Sep 8, 2005, $2M — New England Partners, Maryland Venture Fund, Crocker Mountain Capital

## Investors

- New England Partners (https://capitalatlas.ai/funds/new-england-partners) — Series A
- Maryland Venture Fund (https://capitalatlas.ai/funds/maryland-venture-fund) — Series A
- Crocker Mountain Capital (https://capitalatlas.ai/funds/crocker-mountain-capital) — Series A